Tempest Therapeutics Inc.
Organization details
- Legal name
- Tempest Therapeutics Inc.
- Former names
- Millendo Therapeutics, Inc. OvaScience, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Brisbane
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- TPST
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001544227
- EIN
- 45-1472564
Board of directors
-
Christine A. Pellizzari · DirectorSince 2023
-
Geoffrey Nichol · DirectorSince 2023
-
John D. Yee · DirectorSince 2026
-
John W. Frederick · DirectorSince 2026
-
Matthew Angel · Director · CEO and PresidentSince 2026
-
Michael Raab · DirectorSince 2023
-
Nancy Freda Smith · DirectorSince 2026
-
Ronit Simantov · DirectorSince 2023
-
Stephen R. Brady · Director · President and CEOSince 2023
-
Thomas W. Dubensky · Director · PresidentSince 2023
-
William Drake Richey · DirectorSince 2026
Chief executives
Director election results
Annual meeting of November 9, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
97.0%
-
97.7%
Board connections
3 of this board's directors also sit on 4 other boards. 4 are in the same sector.
-
Ardelyx Inc. Same sectorvia Michael Raab
-
Ernexa Therapeutics Inc. Same sectorvia Matthew Angel
-
Imunon Inc. Same sectorvia Christine A. Pellizzari
-
NeuroSense Therapeutics Ltd. Same sectorvia Christine A. Pellizzari
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $1,000,002
- 2 purchases by 1 insider
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 24, 2026 | Matthew Angel Director, Officer (CEO and President), 10% owner | Open-market purchase | +231,482 | $2.16 | $500,001 |
| Mar 24, 2026 | Matthew Angel Director, Officer (CEO and President), 10% owner | Open-market purchase | +231,482 | $2.16 | $500,001 |
| Aug 12, 2024 | Versant Venture Capital VI, L.P. 10% owner | Open-market sale | −387,999 | $1.10 | $426,799 |
| Aug 8, 2024 | Versant Venture Capital VI, L.P. 10% owner | Open-market sale | −400,000 | $1.35 | $540,000 |
| Jul 3, 2024 | Stephen R. Brady Director, Officer (President and CEO) | Open-market purchase | +35,000 | $2.11 | $73,850 |
| Jul 2, 2024 | Whiting Samuel Officer (Chief Medical Officer) | Open-market purchase | +4,672 | $2.13 | $9,951 |
| Jun 28, 2024 | Trojanowski Justin Officer (Corporate Controller) | Open-market purchase | +7,500 | $2.16 | $16,200 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Tempest Therapeutics Inc.
Who is the CEO of Tempest Therapeutics Inc.?
Matthew Angel has been Tempest Therapeutics Inc.'s CEO and President since February 2026.
How many directors are on Tempest Therapeutics Inc.'s board?
Tempest Therapeutics Inc.'s board has 11 directors: Christine A. Pellizzari, Geoffrey Nichol, John D. Yee, John W. Frederick, Matthew Angel, Michael Raab, Nancy Freda Smith, Ronit Simantov, Stephen R. Brady, Thomas W. Dubensky and 1 other.
Are Tempest Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Tempest Therapeutics Inc. insiders bought $1.0 million of shares in 2 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="tempest-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.